Price T Rowe Associates Inc Replimune Group, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 10,853,832 shares of REPL stock, worth $134 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,853,832
Previous 10,962,883
0.99%
Holding current value
$134 Million
Previous $133 Million
20.29%
% of portfolio
0.01%
Previous 0.02%
Shares
18 transactions
Others Institutions Holding REPL
# of Institutions
170Shares Held
78.5MCall Options Held
69.4KPut Options Held
216K-
Baker Bros. Advisors LP New York, NY11MShares$136 Million1.28% of portfolio
-
Redmile Group, LLC San Francisco, CA4.9MShares$60.4 Million5.02% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$58.1 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.91MShares$48.2 Million9.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.83MShares$47.3 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $608M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...